{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:53Z","timestamp":1787698493650,"version":"build-2784847793"},"reference-count":58,"publisher":"American Society for Clinical Investigation","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH NINDS","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"SymBio Pharmaceuticals Limited, Tokyo, Japan","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:p>\n                    Epstein-Barr virus (EBV) is of growing interest for its potential role in neurodegenerative diseases such as multiple sclerosis (MS) and its possible utility as a therapeutic target in herpesvirus-associated chronic diseases. The effects of brincidofovir (BCV) on EBV reactivation were evaluated in vitro using EBV-infected spontaneous lymphoblastoid cell lines (SLCLs) and peripheral blood mononuclear cells (PBMCs) derived from patients with MS and healthy controls. In addition, a B lymphoblastoid cell line and PBMCs from common marmosets (\n                    <jats:italic>Callithrix jacchus<\/jats:italic>\n                    ) naturally infected with an EBV-related gammaherpesvirus (Callitrichine herpesvirus 3, CalHV-3) were used to measure BCV efficacy in a nonhuman primate model. BCV significantly inhibited gammaherpesvirus reactivation, with decreased lytic and latent viral transcript expression. These results suggest that BCV may be a useful antiviral for inhibiting EBV activity in patients with MS. Additionally, this work further validates the utility of CalHV-3 in marmosets as a translational model for the investigation of successful EBV-targeting therapeutics.\n                  <\/jats:p>","DOI":"10.1172\/jci195764","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T18:00:19Z","timestamp":1764093619000},"source":"Crossref","is-referenced-by-count":3,"title":["Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells"],"prefix":"10.1172","volume":"136","author":[{"given":"Abaigeal","family":"Donaldson","sequence":"first","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine R.","family":"Druker","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monaco","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily H.","family":"Stack","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lee","sequence":"additional","affiliation":[{"name":"Translational Neuroradiology Section, NINDS, NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Bialuk","sequence":"additional","affiliation":[{"name":"Department of General and Experimental Pathology, Medical University of Bia\u0142ystok, Bia\u0142ystok, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Frazier","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-7181","authenticated-orcid":true,"given":"Irene","family":"Cortese","sequence":"additional","affiliation":[{"name":"Experimental Immunotherapeutics Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Narver","sequence":"additional","affiliation":[{"name":"Animal Health and Care Section, NINDS, NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hazama","sequence":"additional","affiliation":[{"name":"SymBio Pharmaceuticals Limited, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Yoshida","sequence":"additional","affiliation":[{"name":"SymBio Pharmaceuticals Limited, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie T.","family":"Krug","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"B1"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.187"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq6978"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00770-5"},{"key":"B6"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226436"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80622-6"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430707"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/2281056a0"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v13122344"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03824-y"},{"key":"B13"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200003000-00023"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70267-4"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20820"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24932"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00980-19"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.03.042"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1017484"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515591862"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811974115"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.3.1224"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-7-1621"},{"issue":"1","key":"B25","first-page":"59","article-title":"Fatal lymphoproliferative disease associated with a novel gammaherpesvirus in a captive population of common marmosets","volume":"50","author":"Ramer","year":"2000","journal-title":"Comp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.23.12055-12068.2002"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00145"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9020116"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615601933"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.178"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.3.1440-1450.2006"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03428-12"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/srep11767"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303688"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2004.06.008"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/656717"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/v3020063"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00974-10"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.144"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.07.021"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12340"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200149"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01699-6"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.21.11798-11806.2004"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/133.7.2485S"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01925-18"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00520"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/v15040949"},{"key":"B50"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.245462"},{"key":"B52","unstructured":"Suzuki T. New Business Development: Advances Made in BCV. SymBio Pharmaceuticals Ltd.; 2023. https:\/\/www.symbiopharma.com\/ir_e\/pdf\/20230116_FR_4582_E.pdf"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.580"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1515\/nipt-2023-0011"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113069"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9487-z"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01894-22"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/195764\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:04:22Z","timestamp":1779210262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/195764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2026,1,16]]}},"alternative-id":["10.1172\/JCI195764"],"URL":"https:\/\/doi.org\/10.1172\/jci195764","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"e195764"}}